Compass Therapeutics reports Phase 1 CTX-8371 data showing 33% ORR at top doses

• Compass Therapeutics flagged Phase 1 results for CTX-8371, a dual PD-1 and PD-L1 checkpoint blocker, for presentation at the 2026 ASCO Annual Meeting in Chicago on May 30.
• The early readout showed signs of anti-tumor activity in heavily pretreated patients whose cancers had progressed on prior checkpoint inhibitors, with responses described as deep and durable in several tumor types.
• The safety profile appeared manageable in dose escalation, with no dose-limiting toxicities reported and most treatment-related side effects described as mild.
• Cohort expansions have started in non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma, with additional data expected in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211700PRIMZONEFULLFEED9724880) on May 21, 2026, and is solely responsible for the information contained therein.